Administration of MRI contrast agents has been shown to improve diagnostic accuracy of MRI. This study will compare a new agent, MP-177/10 Injection, with one already approved by the FDA, gadopentetate dimeglumine (Gd-DTPA). This is a Phase III, multicenter, double-blind, randomized, parallel group, comparative study which evaluates the safety, tolerability, and dfficacy of MP-1177/10 as compared with Gd-DTPA in patients referred for a contrast-enhanced MRI, highly suspected of having liver pathology.
Showing the most recent 10 out of 565 publications